AWG News

Home / AWG News

Acurx Pharmaceuticals Joins the Antimicrobials Working Group

WASHINGTON, Aug. 5, 2021 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the addition of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (Acurx) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG’s membership to 13 antimicrobial drug companies. Acurx is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA). Their lead product candidate, ibezapolstat, is a first-in-class of a new class of...

Read More

Crestone Joins Antimicrobials Working Group

WASHINGTON, June 8, 2021 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the addition of Crestone, Inc. (Crestone) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG’s membership to 12 antimicrobial drug companies. Crestone is a clinical stage biopharmaceutical company focused on inventing and developing novel small molecule drugs for serious bacterial infections, including C. difficile Infection (CDI), resistant Gram-positive infections such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE), and chronic infections such as nontuberculous mycobacterial (NTM) disease. Their lead product candidate, CRS3123, for...

Read More

UTILITY Therapeutics Joins Antimicrobials Working Group

WASHINGTON, February 17, 2021 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the addition of UTILITY therapeutics Ltd. (UTILITY) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG’s membership to 13 antimicrobial drug companies. UTILITY is focused on developing and commercializing antibiotics in the United States to address the significant threat faced by healthcare systems and patients from multi-drug resistant bacterial infections. UTILITY has exclusive U.S. commercial rights to two European-approved antibiotics, pivmecillinam and mecillinam, for the treatment of urinary tract infections (UTI). Pivmecillinam is an...

Read More

Antimicrobials Working Group Announces Updates to Leadership Team

WASHINGTON, Jan. 27, 2021 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the appointment of a new Chairperson, Ciara Kennedy, Ph.D., President and Chief Executive Officer of Amplyx Pharmaceuticals, Inc. Dr. Kennedy replaces Evan Loh, M.D., Chief Executive Officer of Paratek Pharmaceuticals, Inc., who has completed his two-year term as Chairman of AWG. Dr. Loh will remain on the AWG Executive Committee. AWG also announced that Executive Committee member Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics, has been appointed Vice Chair. “Ciara is an exceptional leader whose combined scientific expertise and business acumen will serve AWG well as...

Read More

Antimicrobials Working Group Announces Updates to Leadership Team

WASHINGTON, Jan. 17, 2019 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the appointment of a new Chairman, Evan Loh, M.D., President, Chief Operating Officer and Chief Medical Officer of Paratek Pharmaceuticals, Inc. Dr. Loh replaces Jeffrey Stein, Ph.D., President and Chief Executive Officer of Cidara Therapeutics, whose two-year term as Chairman of AWG has expired. Dr. Stein will remain on the AWG Executive Committee. The AWG also announced that Ciara Kennedy, Ph.D., President and Chief Executive Officer of Amplyx Pharmaceuticals, Inc. has been appointed as Vice Chair, joining Vice Chair Michael Dunne, M.D., Chief Scientific Officer of Iterum Therapeutics. Additionally, Ted Schroeder, Chief Executive Officer...

Read More

VenatoRx Pharmaceuticals Joins Antimicrobials Working Group

WASHINGTON, Jan. 3, 2019 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the addition of VenatoRx Pharmaceuticals, Inc. to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG’s membership to 15 antimicrobial drug companies. VenatoRx is a world leader in antibacterial and antiviral drug research and development. The Company’s lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor (BLI) that features uniquely potent and selective activity against both serine- and metallo-beta lactamases. VenatoRx believes that VNRX-5133, in a fixed combination with the fourth generation cephalosporin, cefepime, has the potential...

Read More

Qpex Biopharma Joins Antimicrobials Working Group

WASHINGTON, Oct. 30, 2018 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the addition of Qpex Biopharma, Inc. (Qpex) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. Qpex is developing a pipeline of agents addressing critical needs for the treatment of infectious diseases in the inpatient and outpatient settings. The company has an established research and development (R&D) partnership with Biomedical Advanced Research and Development Authority (BARDA) that provides the potential to support the development of a portfolio of new antibiotics to fight drug-resistant, gram-negative infections. The new addition brings AWG’s membership to...

Read More

Summit Therapeutics Joins Antimicrobials Working Group

WASHINGTON, July 30, 2018 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the addition of Summit Therapeutics plc (NASDAQ: SMMT; AIM: SUMM) (Summit) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. Summit is an international biopharmaceutical company developing new mechanism antibiotics for C. difficile infection and gonorrhea and is using its proprietary Discuva Platform to expand its pipeline. The new addition brings AWG’s membership to 19 antimicrobial drug and diagnostic device development companies in the United States and Europe. “Summit Therapeutics is committed to antibiotic innovation, and is one of several AWG member companies with locations both...

Read More

Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018

WASHINGTON, June 6, 2018 /PRNewswire/ — The Antimicrobials Working Group (AWG) today announced that 13 of its member companies will present data from their clinical and research programs at the American Society for Microbiology’s ASM Microbe 2018 meeting to be held June 7-11 in Atlanta, GA. ASM Microbe showcases the best microbial sciences in the world and provides a one-of-a-kind forum to explore the complete spectrum of microbiology from basic science to translation and application. “ASM Microbe provides a valuable opportunity for AWG member companies throughout the antimicrobial drug development arena to highlight innovation and demonstrate progress in the fight to defeat drug resistant infections,”...

Read More

X-Biotix Therapeutics, Inc. Secures $7 million in Series A Financing

X-Biotix Therapeutics, Inc. Secures $7 million in Series A Financing Announces Key Additions to Board of Directors and Senior Management WALTHAM, Mass. April 24, 2018 – X-Biotix Therapeutics, Inc. (X-Biotix), a biotechnology company focused on the discovery and development of novel small molecule antibiotic scaffolds targeting multidrug-resistant (MDR) Gram-negative pathogens, announced that the company has secured $7 million in a Series A financing from a group of private investors. Proceeds of the financing will enable X-Biotix to advance its pipeline of novel antibiotic candidates targeting a wide range of biological targets in essential pathways of Gram-negative bacterial cells. The company...

Read More

Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

WASHINGTON, April 20, 2018 /PRNewswire/ — The Antimicrobials Working Group (AWG) today announced that thirteen of its member companies will present data from their clinical and research programs at the annual meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) to be held April 21 – 24 in Madrid, Spain. ECCMID is an annual scientific meeting that brings together the leading experts in the fields of clinical microbiology, infectious disease and infection control from across the globe to present and discuss the latest developments in the laboratory and in the clinic to advance research in a wide array of infectious diseases. “AWG...

Read More

The Antimicrobials Working Group Announces the Appointment of Dr. Michael Dunne as Vice Chair

WASHINGTON, Jan. 30, 2018 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today that Michael Dunne, M.D., Chief Scientific Officer of Iterum Therapeutics, has been appointed as Vice Chair, joining Vice Chair Evan Loh, M.D., President, Chief Operating Officer and Chief Medical Officer of Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) and Chairman Jeffrey Stein, Ph.D., President and CEO of Cidara Therapeutics, Inc. (NASDAQ: CDTX). “On behalf of AWG, I would like to welcome Dr. Dunne as Vice Chair,” said Dr. Jeffrey Stein, AWG Chairman. “As an infectious disease physician and long-standing member of AWG, the Board of Directors is confident Dr. Dunne will contribute valuable insight in the position as...

Read More